Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Zacks05-21

Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold (NLF) study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437608428?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z584cE9dmmrKrF4Y5puxGg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/fcaf2bfdd08336aba6c54d27476b6e54","is_english":true,"pubTime":"2024-05-21 22:57","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2437608428","market":"us","top_or_hot":-1,"title":"Evolus (EOLS) Releases Favorable Dermal Fillers Study Data","media":"Zacks","content":"<div>\n<p>Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold (NLF) study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these ...</p>\n\n<a href=\"https://finance.yahoo.com/news/evolus-eols-releases-favorable-dermal-145700401.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus (EOLS) Releases Favorable Dermal Fillers Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus (EOLS) Releases Favorable Dermal Fillers Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/evolus-eols-releases-favorable-dermal-145700401.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold (NLF) study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these ...</p>\n\n<a href=\"https://finance.yahoo.com/news/evolus-eols-releases-favorable-dermal-145700401.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/evolus-eols-releases-favorable-dermal-145700401.html","article_id":"2437608428","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z584cE9dmmrKrF4Y5puxGg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/fcaf2bfdd08336aba6c54d27476b6e54"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437608428","pubTimestamp":1716303420,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold  study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company’s strategic expansion within the aesthetic device market.These promising results bolster the company’s upcoming Premarket Approval Application  for the U.S. launch of Evolus’s dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days.The addition of Evolysse fillers to the company’s portfolio will perfectly complement Evolus’ flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%.This expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs.Some better-ranked stocks in","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc.","HIMS":"Hims & Hers Health Inc.","BK4588":"碎股","MEDP":"Medpace Holdings Inc.","BK4007":"制药","HITI":"High Tide Inc.","BK4196":"保健护理服务","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念"},"translate_title":"Evolus(EOLS)发布有利的真皮填充物研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":1,"HIMS":1,"HITI":1,"MEDP":1},"content_text":"Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold (NLF) study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company’s strategic expansion within the aesthetic device market.\nThese promising results bolster the company’s upcoming Premarket Approval Application (“PMA”) for the U.S. launch of Evolus’s dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days.\nStrategic Significance\nThe addition of Evolysse fillers to the company’s portfolio will perfectly complement Evolus’ flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%.\nThis expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs.\nThe company in this regard emphasized the consistency of the U.S. study results with previous European trials, enhancing confidence in the forthcoming FDA submission. One trial investigator in this process noted the precision and efficacy of the Evolysse fillers, particularly praising the novel “Cold Technology” used in their manufacture.\nImage Source: Zacks Investment Research\nStudy Insights\nThe pivotal study utilized a multicenter, split-face design, comparing Evolysse Lift and Smooth against Restylane-L in 140 patients. Both Evolysse products not only met the primary endpoint of non-inferiority but also demonstrated superiority in reducing NLF severity over a 12-month period. Importantly, the safety profiles of Evolysse fillers were comparable to their respective controls, with no serious adverse events reported.\nMarket Prospects\nGoing by a Coherent Market Insights report, the global aesthetic neurotoxin market is poised for significant growth, projected to expand from $9.01 billion in 2024 to $19.76 billion by 2031, at a CAGR of 11.9%. Key drivers include the rising geriatric population and increasing consumer awareness of cosmetic procedures. Botox and dermal fillers dominate this market, with Botox expected to hold more than 35% share by 2031. Growing demand for minimally invasive treatments and combination therapies further fuels this expansion. Notably, the lip enhancement segment, particularly using hyaluronic acid-based fillers, is set to grow rapidly, driven by the popularity of fuller lips among millennials.\nShare Price Performance\nYear to date, shares of EOLS have gained 27.5% compared with the industry’s 4.3% rise.\nZacks Rank and Key Picks\nEvolus currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, High Tide HITI and Medpace MEDP. Each of them sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks Rank #1 stocks here.\nHims & Hers Heath stock has rallied 53.3% in the past year. Earnings estimates for the company have risen from 10 cents to 18 cents in 2024 and from 23 cents to 32 cents in 2025 in the past 30 days.\nHIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.\nEstimates for High Tide’s 2024 earnings per share have remained unchanged in the past 30 days. Shares of the company have surged 57.9% upward in the past year against the industry’s fall of 0.6%.\nHITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%. In the last reported quarter, it delivered an earnings surprise of 100%.\nEstimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $10.53 in the past 30 days. Shares of the company have risen 87.6% in the past year compared with the industry’s 5% growth.\nMEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMedpace Holdings, Inc. (MEDP) : Free Stock Analysis Report\nEvolus, Inc. (EOLS) : Free Stock Analysis Report\nHims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report\nHigh Tide Inc. (HITI) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437608428"}